Glioblastoma multiforme Clinical Trials

None

None

None

Glioblastoma adaptive global innovative learning environment

The investigational drugs that will be used in this research study are temozolomide for newly diagnosed glioblastoma and Lomustine for recurrent glioblastomas.

Investigating Potential of Personalized Biomarkers in Redefining Treatment Response in Patients with Glioblastoma using Multiparametric MRI and Liquid Biopsy

Analysis of these results will hopefully have a major impact on precision diagnostics in clinical management of GBM patients, creating personalized therapeutics.

Immune Impact of Bevacizumab in Patients with Recurrent Glioblastoma

40.0

Pilot Surgical PK Study of BGB324 in Recurrent Glioblastoma Patients

3.0

A PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF NIRAPARIB AND TUMOR-TREATING FIELDS IN RECURRENT GLIOBLASTOMA

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and is near uniformly fatal. Only three treatments have been approved by the US FDA for GBM in the past 2 decades: temozolomide, bevacizumab, and, most recently, tumor-treating fields (TTFields).

A pilot study evaluating in vivo PARP-1 expression with18F-FluorThanatrace positron emission tomography (PET/CT) in glioblastoma

This is a companion imaging study that plans to enroll adult subjects with recurrent glioblastoma that meet the eligibility criteria for a treatment trial entitled A phase II study evaluating the efficacy and safety of niraparib and tumor-treating fields in recurrent glioblastoma, IRB 832694/UPCC 03319.

A Phase II Study of the Anti-GITR Agonist INCAGN01876 and the PD-1 Inhibitor INCMGA00012 in Combination with Stereotactic Radiosurgery in Recurrent Glioblastoma

The following protocol is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and SRS for recurrent GBM. We hypothesize that the proposed regimen will be safe and stimulate a robust anti-tumor immune response and result in improved tumor responses.